Literature DB >> 31723014

Building a Better Test for Piperacillin-Tazobactam Susceptibility Testing: Would that It Were So Simple (It's Complicated).

Andrew Henderson1,2, Romney Humphries3,4.   

Abstract

In this issue of the Journal of Clinical Microbiology, S. García-Fernandez, Y. Bala, T. Armstrong, M. Garcia-Castillo, et al. (J Clin Microbiol 58:e01042-19, 2020, https://doi.org/10.1128/JCM.01042-19) describe the performance of a reformulated Etest for piperacillin-tazobactam. The analytical performance data are excellent, but in the face of recent emerging data on the inefficacy of piperacillin-tazobactam for certain organisms that test susceptible, the value of piperacillin-tazobactam MICs is controversial. Evaluation of MICs in the context of the modal MIC for Enterobacterales and Pseudomonas aeruginosa, the variability of MIC tests, and, possibly, resistance mechanisms is important to the optimum use of this antimicrobial.
Copyright © 2020 American Society for Microbiology.

Entities:  

Year:  2020        PMID： 31723014      PMCID： PMC6989057          DOI： 10.1128/JCM.01649-19

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  8 in total

1.  Point-Counterpoint: Differences between the European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute Recommendations for Reporting Antimicrobial Susceptibility Results.

Authors:  Gunnar Kahlmeter; Christian G Giske; Thomas J Kirn; Susan E Sharp
Journal:  J Clin Microbiol       Date:  2019-08-26       Impact factor: 5.948

2.  Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment of Bloodstream Infections Due to AmpC β-Lactamase-Producing Enterobacteriaceae.

Authors:  Lucy Cheng; Brian C Nelson; Monica Mehta; Nikhil Seval; Sarah Park; Marla J Giddins; Qiuhu Shi; Susan Whittier; Angela Gomez-Simmonds; Anne-Catrin Uhlemann
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

3.  Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Complex.

Authors:  Sergio García-Fernández; Yohann Bala; Tom Armstrong; María García-Castillo; C A Burnham; Meghan A Wallace; Dwight Hardy; Gilles Zambardi; Rafael Cantón
Journal:  J Clin Microbiol       Date:  2020-01-28       Impact factor: 5.948

Review 4.  Pharmacokinetic evaluation of piperacillin-tazobactam.

Authors:  Yoshiro Hayashi; Jason A Roberts; David L Paterson; Jeffrey Lipman
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-08       Impact factor: 4.481

5.  MIC-based dose adjustment: facts and fables.

Authors:  Johan W Mouton; Anouk E Muller; Rafael Canton; Christian G Giske; Gunnar Kahlmeter; John Turnidge
Journal:  J Antimicrob Chemother       Date:  2018-03-01       Impact factor: 5.790

6.  Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.

Authors:  Maroun M Sfeir; Gulce Askin; Paul Christos
Journal:  Int J Antimicrob Agents       Date:  2018-08-03       Impact factor: 5.283

7.  OXA-1 β-lactamase and non-susceptibility to penicillin/β-lactamase inhibitor combinations among ESBL-producing Escherichia coli.

Authors:  David M Livermore; Michaela Day; Paul Cleary; Katie L Hopkins; Mark A Toleman; David W Wareham; Camilla Wiuff; Michel Doumith; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2019-02-01       Impact factor: 5.790

8.  Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.

Authors:  Patrick N A Harris; Paul A Tambyah; David C Lye; Yin Mo; Tau H Lee; Mesut Yilmaz; Thamer H Alenazi; Yaseen Arabi; Marco Falcone; Matteo Bassetti; Elda Righi; Benjamin A Rogers; Souha Kanj; Hasan Bhally; Jon Iredell; Marc Mendelson; Tom H Boyles; David Looke; Spiros Miyakis; Genevieve Walls; Mohammed Al Khamis; Ahmed Zikri; Amy Crowe; Paul Ingram; Nick Daneman; Paul Griffin; Eugene Athan; Penelope Lorenc; Peter Baker; Leah Roberts; Scott A Beatson; Anton Y Peleg; Tiffany Harris-Brown; David L Paterson
Journal:  JAMA       Date:  2018-09-11       Impact factor: 56.272
  8 in total
  3 in total

1.  Disk Correlates for Revised Clinical and Laboratory Standards Institute Enterobacterales Piperacillin-Tazobactam MIC Breakpoints.

Authors:  Romney Humphries; Pranita D Tamma; Amy J Mathers
Journal:  J Clin Microbiol       Date:  2022-04-21       Impact factor: 11.677

2.  Performance of dRAST on Prospective Clinical Blood Culture Samples in a Simulated Clinical Setting and on Multidrug-Resistant Bacteria.

Authors:  Alicia Y W Wong; Alexander T A Johnsson; Volkan Özenci
Journal:  Microbiol Spectr       Date:  2022-03-02

3.  CON: Testing for ESBL production is unnecessary for ceftriaxone-resistant Enterobacterales.

Authors:  Amy J Mathers; James S Lewis
Journal:  JAC Antimicrob Resist       Date:  2021-05-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.